[PDF] Top 20 New development in CAR-T cell therapy
Has 10000 "New development in CAR-T cell therapy" found on our website. Below are the top 20 most common "New development in CAR-T cell therapy".
New development in CAR-T cell therapy
... same T cell population. Of the two receptors, one is a CAR containing CD3z signaling domain alone and specific for one antigen, which can provide the T cell activation signaling ...the ... See full document
11
The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL
... Neurotoxicity, or CAR T-related encephalopathy syn- drome (CRES), can occur before, in association with, or after CRS. Around 40% of patients who received a CTL019 infusion experienced some sort of ... See full document
12
CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia
... receptor-modified T-cells (CAR-T) represent one of the few practice-changing therapies for this subgroup of ...first CAR-T approved by the US Food and Drug Administration, showed ... See full document
14
Treating Cancer With Engineered T Cell Therapies: Murine and Canine Models of Safety and Efficacy
... of T cells from the peripheral blood of both humans and dogs with advanced hematological neoplasia can be challenging and the inability to generate a CAR T cell product from these patients has ... See full document
197
Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy
... Establishment of prediction model for grade 4 – 5 infection A total of 81 serum specimens were obtained from 109 patients, including 10 specimens of grade 4–5 infection, 10 specimens of grade 3–5 CRS and 61 specimens of ... See full document
11
Therapeutic potential of CAR-T cell-derived exosomes: a cell- free modality for targeted cancer therapy
... from CAR-T cells and the status of in vivo expansion of these cells cannot be appropriately controlled, which is the potential source of adverse events, such as CRS, cytokine storm and “on- target, ... See full document
12
T cell senescence and CAR-T cell exhaustion in hematological malignancies
... malignancies. CAR-T and TCR-T cell therapy makes use of functionally active T cells isolated from ...These T cells are reconstructed and expanded ex vivo to recognize ... See full document
9
Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity
... the development of efficient in vivo delivery systems, careful testing of different vectors, transgenes, and T cell targets, and development of genetically engineered, spontaneous glioma ... See full document
13
Critical factors in chimeric antigen receptor-modified T-cell (CAR-T) therapy for solid tumors
... optimal T-cell subset as the material for preparing CAR-T can enhance the effect of the ...endogenous T cells, after receiving the pMHC signal, naive T cells differentiate into ... See full document
12
Liposomal Vincristine as a Bridge Therapy Prior to CAR-T Therapy in Relapsed and Refractory Diffuse Large B-Cell Lymphoma?
... and new and worsening generalized ...stem cell transplant with inpatient high-dose chemotherapy with stem cell rescue therapy for primary relapsed ...blood cell (WBC) greater than 30K ... See full document
6
Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis
... of CAR-T cell therapy and iden- tify gaps in current practice and ...investigate CAR-T cell therapy among patients with solid ... See full document
6
CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy
... [75]. New inhibitors for inflammasomes are being studied ...represent new families of targeted ...macrophage cell surface that represents a “do-not-eat-me” immune checkpoint molecule [78, ...TCR- ... See full document
5
Clinical trials of CAR-T cells in China
... tisagenlecleucel CAR-T ther- apy relies on transduction of autologous T cells from ...Universal CAR-Ts have been generated by inactivating HLA class I molecules and used successfully in ... See full document
10
Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia
... 21 patients). Four of the patients did not receive alemtu- zumab (FC regimen) and failed to have UCART19 ex- pansion. These four patients did not respond to the treatment. Among the rest of the 17 patients who re- ceived ... See full document
11
Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy
... thelial cell and pericyte ...bi-specific CAR-T cell infusion, just at the onset of grade 3 neurotoxicity (unpublished ...receiving CAR-T cells, which should be attributable to a ... See full document
10
Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
... in CAR-T cell ...ing therapy could significantly improve the therapeutic ...to cell infusion, significantly higher than ...of CAR-T cells in vivo and disease-free survival ... See full document
7
Case Report Achievement of disease control with dasatinib after CAR T-cell therapy for relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia: a case report and literature review
... Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allo- geneic hematopoietic stem-cell transplanta- tion without ... See full document
7
Current Progress in CAR-T Cell Therapy for Solid Tumors
... Multispecific CAR-T cells have a potential advantage over unispecific CAR-T cells in avoiding on-target/off-tumor toxicities ...multispecific CAR-T cells led to specific tissue ... See full document
13
CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation
... Manufacturing, New Brighton, MN). Three days later, CAR or CAR +ICR-modified T cells were added to tumor cells to achieve a T cell:tumor cell ratio of 1:10 in the presence of 400 ... See full document
13
CAR-T cell therapy in neuro-oncology: applications and toxicity
... CAR-T therapy has had promising results in hematological malignancies and has revolutionized the immunotherapy field in the last several ...this therapy, its mechanism of action and ... See full document
12
Related subjects